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Abstract
Background: The genetics of advanced biliary tract cancers (BTC), which encompass intra- and extra-hepatic
cholangiocarcinomas as well as gallbladder carcinomas, are heterogeneous and remain to be fully defined.
Methods: To better characterize mutations in established known oncogenes and tumor suppressor genes we
tested a mass spectrometric based platform to interrogate common cancer associated mutations across a panel of
77 formalin fixed paraffin embedded archived BTC cases.
Results: Mutations among three genes, KRAS, NRAS and PIK3CA were confirmed in this cohort. Activating
mutations in PIK3CA were identified exclusively in GBC (4/32, 12.5%). KRAS mutations were identified in 3 (13%)
intra-hepatic cholangiocarcinomas and 1 (33%) perihillar cholangiocarcinoma but were not identified in gallbladder
carcinomas and extra-hepatic cholangiocarcinoma.
Conclusions: The presence of activating mutations in PIK3CA specifically in GBC has clinical implications in both
the diagnosis of this cancer type, as well as the potential utility of targeted therapies such as PI3 kinase inhibitors.
Background
Biliary tract cancer (BTC) includes a spectrum of inva-
sive adenocarcinomas including cholangiocarcinomas
arising from within the liver parenchyma, peri-hilar, or
distal biliary tree, as well as carcinoma arising from the
gallbladder (GBC). Regardless of the site of origin, these
t u m o r sd i s p l a yar e m a r k a b l ys imilar histologic appear-
ance, variable amount of gland formation, and an exu-
berant desmoplastic stromal reaction. These tumors
share an anatomic origin in the biliary system; however,
there are important differences in disease behavior,
molecular profiles, and sensitivity to therapy. In general
GBC tends to exhibit greater initial sensitivity to che-
motherapy but confers a shorter overall survival com-
pared with cholangiocarcinoma (CC) [1]. Historically,
treatment for BTC has not taken into account the
anatomic site of origin of the tumor or molecular
profile and the mainstay of treatment is cytotoxic
chemotherapy, as these tumors are commonly diag-
nosed at advanced stages when surgical resection is not
an option.
While a spectrum of mutations in established onco-
genes and tumor suppressors have been identified in
BTC the real frequency of such mutations and the rela-
tionship of mutations with each other has been hard to
define. KRAS, BRAF, EGFR, and PIK3CA mutations are
found in subsets of both GBC and CC [2-11]. Mutations
in the tumor suppressor genes CDKN2A, TP53 and
SMAD4 have also been identified [12-16]. The relation-
ship of these mutations to each other as well as the fre-
quency of each mutation within subsets of BTC is not
yet fully explored. Additionally, many established muta-
tions identified in other cancer remain to be evaluated
in BTC.
Increasingly, cancer genetics are being applied to assist
in making therapeutic decisions in cancer treatment.
HER2NEU gene amplification, EGFR, and KRAS muta-
tion testing are all used routinely clinically to determine
an individual’s likelihood of benefit from treatment with
specific targeted anti-cancer therapies [17-19]. Building
on this paradigm emerging classes of drugs, such as
BRAF inhibitors, are being tested at the earliest phases
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patients who are believed to have the greatest potential
for benefit [20]. Given that underlying tumor genetics
may predict drug sensitivity- particularly in emerging
classes of targeted anticancer agents- uncovering pat-
terns of genetic change within BTC is critical to improv-
ing therapy as well as gaining insight into disease
biology.
In order to better characterize genetics of these
tumors we conducted genotyping across 77 formalin
fixed paraffin embedded (FFPE) surgical specimens
including GBC as well as both intra- and extra-hepatic
CC using “OncoMap”. OncoMap is a high-throughput
mass-spectrometric based cancer gene mutation profil-
ing platform incorporating a collection of OncoMap 3
core -460 assays interrogating known mutations in 33
cancer genes [21,22]. Using genomic profiling with
OncoMap coupled with an analytical mutation-calling
algorithm and orthogonal validation step, numerous
mutations have been identified in genomic DNA from
both frozen and FFPE tumor tissue with a high degree
of specificity and sensitivity [21]. This approach was
selected given the focus of this platform on selecting
established mutations highlighting pathways with emer-
ging therapies, as well as the previously observed genetic
heterogeneity of BTC. The primary goal was to identify
novel or “druggable” mutations in biliary carcinoma.
Methods
BTC Samples
Samples were identified with institutional review board
(IRB) approval through a search of pathologic cases of
the gallbladder and biliary tract - resected or biopsied-
available from archived tissues at the Massachusetts
General Hospital between 1998 and 2008. In total 33
gallbladder, 29 IHCC and perihilar, and 15 middle com-
mon bile duct and intra-pancreatic biliary carcinomas
were included to capture the broadest range of BTC.
Hematoxylin and eosin (H&E) stainings were evaluated
to confirm the diagnosis and to identify samples with the
greatest tumor cellularity (ideally > 50%). Tumors were
classified based on anatomic origin within the biliary tree
and placed in 3 groups- gallbladder, intra-hepatic and
perihilar, and distal common bile duct (CBD) and intra-
pancreatic. Histological evaluation by two expert patholo-
gists was used to distinguish distal bile duct carcinomas
from pancreatic ductal adenocarcinomas, with the dis-
tinction based primarily on the pattern of infiltration and
the relationship of the tumor to the bile duct.
Extraction of Tumor Genomic DNA
For FFPE samples, tissue from representative blocks
with areas of >50% tumor cellularity were sectioned
(five 10 micrometer sections) and serial H&E-stained
slides were obtained from each block. Areas of > 50%
tumor cellularity were dissected from slides using a scal-
pel and scraped into micro-centrifuge tubes. Diagnoses
were confirmed by independent histopathological
review. DNA was extracted from FFPE according to the
manufacturer’s directions. The quality of DNAs was
evaluated by quantification (Picogreen) and PCR amplifi-
cation of fragments of 100-200bp in length.
Mass Spectrometric Genotyping
A two-step process was used as previously described
[21], where candidate mutations identified using Onco-
M a pt e c h n o l o g yw e r es u b s e q u e n t l ys u b j e c tt oas e c o n d
round of homogenous Mass-Extend (hME) validation,
using independent primers and probes and non-whole
genome amplified DNA. In brief, primers and probes
were pooled, and all assays were validated on the CEPH
panel of human HapMap DNAs (Coriell Institute) as
well as a panel of human cell lines with known muta-
tional status, as described previously [21]. Genomic
DNA from all tumor samples was quantified using
Quant-iT™ PicoGreen
® dsDNA Assay Kit (Invitrogen,
Carlsbad, California) and subjected to whole-genome
amplification (WGA), as described previously [21]. After
quantification and dilution of genome-amplified DNA,
mass spectrometric genotyping using iPLEX chemistries
was performed as described previously [21]. An auto-
mated mutation-calling algorithm was performed to
identify candidate mutations and putative mutations
were further filtered by a manual review. Candidate
mutations identified were subsequently subject to a sec-
ond round of hME validation, using independent pri-
mers and probes and a multi-base extension hME
chemistry. Conditions for hME validation were as pre-
viously described [21]. All mutations identified in WGA
material were confirmed, using a second independent
assay, on unamplified DNA.
Statistical Analysis
Fishers exact test was applied to determine the associa-
tion of PIK3CA mutation with GBC.
Results
Identification of mutations in BTC
Mutations in KRAS, NRAS, and PIK3CA were identified
as outlined in Table 1 and 2. In summary the process
leading to positive identification of mutations involved a
two-step process was used as previously described [21],
where candidate mutations identified using OncoMap
technology (all mutations included in initial screen are
listed in Additional file 1 Table S1) were subsequently
subject to a second round of hME validation (for details
see Figure 1). From among the 77 BTC the percentage
of samples that were successfully genotyped indicating
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93.5%. Five samples failed quality control steps designed to
evaluate overall quality of recovered DNA (quality control
measures described in [22] and were not included in sub-
sequent analysis (Figure 1). Of the 72 samples with good
quality DNA, initial OncoMap screening indentified 115
candidate mutations across 24 genes in 65% (47/72) of
samples. These were then ranked into two groups based
on the mass spectrometric profiles and the likelihood that
these represent true mutations referred to as conservative
and aggressive “calls” which comprised 10% (12/115) and
90% (103/115) of possible mutations, respectively (outlined
in Figure 1 and Additional file 1 Table S2).
Candidate mutations across 12 genes (ABL1, APC, BRAF,
EGFR, FGFR3, FLT3, KIT, KRAS, NRAS, PDGFRA,
PIK3CA, MYC,) were then evaluated by an hME approach
on non WGA DNA using independent primers and probes
(for details on specific mutations screened see Additional
file 1 Table S3). All samples that included a candidate
mutation of interest were included in the hME analysis.
Candidate gene mutations included in validation assays
were chosen based on a high prevalence of mutations,
potential for targeting with therapeutics, potential clinical
utility, or novelty. Activating mutations in KRAS, NRAS,
and PIK3CA were confirmed. Among these activating
PIK3CA mutations were unique to gallbladder tumors.
Mutations in gallbladder carcinoma and clinicopathologic
correlates
33 gallbladder carcinomas were analyzed (Table 3).
The mean age of this cohort was 66 years, and
included 25 females and 8 males. Additionally, two
gallbladders with high-grade dysplasia were also evalu-
ated. The majority (n = 27) of these cases were adeno-
carcinomas. In addition, we analyzed 3 adenosquamous
carcinomas, and one case each with the following his-
tologic features: squamous cell carcinoma, colloid car-
cinoma, and undifferentiated carcinomas. PI3K
mutations were specific to carcinomas of the gallblad-
der and were identified in 4 (12.5%) gallbladder carci-
nomas, (p = 0.013 vs. CC). Of the 4 cases with
mutations, 3 were identifiedi na d e n o c a r c i n o m a s ,a n d
1i na na d e n o s q u a m o u sc a r c i n o m a .T h e r ea r en o
appreciable differences in T stage or patient character-
istics between the cohort that showed PI3K mutations
and the group of cases that did not (Table 3). Neither
of the two gallbladders with high-grade dysplasia
showed PI3K mutations.
Table 1 Mutation rates by tumor location
Gallbladder Cancer (32) Intra-hepatic CC (24) Perihilar CC (3) Middle CBD and
Intrapancreatic CC (13)
KRAS 0 (0%) 3 (13%) 1 (33%) 0 (0%)
NRAS 2 (6.3%) 1 (4%) 0 (0%) 0 (0%)
PIK3CA 4 (12.5%) 0 (0%) 0 (0%) 0 (0%)
Table 2 Mutations in BTC
Gene Mutation Source
KRAS G12A Perihilar
KRAS G12C Intra-hepatic
KRAS G12V Intra-hepatic
KRAS G12V Intra-hepatic
NRAS G12D Gallbladder
NRAS G12D Gallbladder
NRAS Q61R Intra-hepatic
PIK3CA E545K Gallbladder
PIK3CA E545K Gallbladder
PIK3CA E542K Gallbladder
PIK3CA E542K Gallbladder
Figure 1 Flow-chart of Identification of Mutations
(Abbreviations: FFPE; formalin fixed paraffin embedded, GBC;
gallbladder carcinoma, IHCC; intra-hepatic cholangiocarcinoma,
CBD; common bile duct, IPC; intra-pancreatic
cholangiocarcinoma).
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cholangiocarcinomas
The cohort included 24 intra-hepatic cholangiocarcino-
mas in which 3 (13%) KRAS mutations and 1 NRAS
(4%) mutation were identified (Table 1). We did not
identify mutations in the single mixed hepatocellular-
cholangiocarcinoma evaluated.
Mutations in perihilar cholangiocarcinomas
One of the three peri-hilar cholangiocarcinomas har-
bored a mutation in KRAS.
Mutations in mid bile duct carcinomas and
intrapancreatic cholangiocarcinomas
This group included 6 adenocarcinomas arising from the
middle third of the bile duct and 9 adenocarcinomas
arising from the intrapancreatic portion of the bile duct.
None of these cases showed mutation among KRAS,
NRAS or BRAF.
Discussion
Mutations in KRAS, NRAS and PIK3CA, all of which
have previously been identified in biliary tract carcino-
mas (for summary of mutations in BTC see Table 4),
were identified in this mutational screen (Reviewed in
[23]) [3,6,24,25]. Furthermore, PIK3CA mutations
appear to be confined to gallbladder carcinomas among
this cohort. Reiner and co-workers have previously iden-
tified PIKCA mutations in one of 11 intra-hepatic cho-
langiocarcinoma and one of 23 GBC previously [11].
However, an association of PIK3CA mutations with
GBC was not appreciated.
Somatic mutations of the PIK3CA gene, which encodes
the p110alpha catalytic subunit of phosphatidylinositol
Table 3 Clinical characteristics of profiled GBC
Mutation Gender Smoking Age T N M Stage Histology Differentiation
PIK3CA E545K F yes 75 1 2 0 1 adenocarcinoma Moderate
PIK3CA E542K F no 83 2 2 0 1 adenocarcinoma Poor
PIK3CA E542K M yes 82 3 1 0 2 adenocarcinoma Moderate
PIK3CA E545K F unknown 53 3 0 0 2 adenosquamous carcinoma Poor
NRAS G12D F no 56 2 1 1 4 adenocarcinoma Poor
NRAS G12D F yes 76 2 0 1 4 adenocarcinoma Moderate
F no 68 3 2 0 2 adenosquamous carcinoma Poor
F no 62 1 2 0 1 adenocarcinoma Moderate
F no 62 3 1 0 2 adenosquamous carcinoma Poor
F unknown 79 4 2 0 3 adenocarcinoma Moderate
F yes 72 3 2 0 2 adenocarcinoma Unknown
F no 57 3 2 0 2 adenocarcinoma Poor
M yes 55 2 1 0 2 adenocarcinoma Poor
F no 87 3 1 0 2 adenocarcinoma Moderate
F no 63 1 0 0 1 adenocarcinoma Moderate
M unknown 54 3 2 0 2 adenocarcinoma Poor
M no 48 3 0 0 2 adenocarcinoma Poor
F yes 52 3 2 1 4 adenocarcinoma Poor
F no 60 3 0 1 4 adenocarcinoma Poor
F yes 76 2 2 0 1 adenocarcinoma Poor
F yes 75 1 2 0 1 adenocarcinoma Moderate
F no 66 4 2 0 3 Undifferentiated carcinoma Poor
F yes 57 4 2 1 4 adenocarcinoma Unknown
F no 72 2 0 0 1 adenocarcinoma Moderate
M yes 81 3 0 1 4 adenocarcinoma Poor
F no 41 2 0 0 1 adenocarcinoma Unknown
M no 68 2 0 0 1 adenocarcinoma Poor
M yes 75 3 0 0 2 adenosquamous carcinoma Moderate
F yes 70 2 2 0 1 adenocarcinoma Poor
F no 74 3 2 0 2 adenocarcinoma Moderate
M no 63 3 2 0 2 adenocarcinoma Poor
F yes 58 2 0 0 1 adenocarcinoma Poor
F no 67 3 0 1 4 adenocarcinoma Unknown
Deshpande et al. BMC Cancer 2011, 11:60
http://www.biomedcentral.com/1471-2407/11/60
Page 4 of 73-kinase (PI3K), are found across a range of cancers
with the highest rates of mutation observed in breast,
colon, endometrial, bladder and hepatocellular cancers
(COSMIC data base). The majority of mutations cluster
at hotspots within exons 9 and 20, which encode the
helical and kinase domains of p110alpha and lead to
activation of downstream pro-growth and survival path-
ways [26]. Importantly mutations in these domains ren-
der cancers sensitive to PI3K specific inhibitors pointing
towards a role for this emerging class of drugs in
cancers harboring these mutations [27]. The PIK3CA
mutations identified in this study, E542K and E545K,
are both located in exon 9.
Activation of the PI3K pathway can be achieved
through a number of molecular mechanisms, including
loss of the PTEN tumor suppressor gene, mutation in
EGFR, and amplifications of ERBB2 (HER2NEU), as well
as through mutation of PIK3CA, as described above
[26,28,29]. ERBB2 over-expression and gene amplifica-
tion is found in ~ 15% of GBC [30]. Additional evidence
implicating the importance of this pathway in BTC
comes from mouse models. A transgenic mutant with
constitutive expression of the ErbB2 in the gallbladder
epithelium develops GBC with a 100% penetrance [30]
and somatic mutation of Pten leads to biliary hyperpla-
sia and intraheaptic cholangiocarcinoma [31]. Taken
together this data points towards deregulation of PI3K
signaling as a key event in the molecular pathogenesis
of some subsets of BTC.
KRAS gene mutations are identified in this series. The
majority of mutations are identified in intra-hepatic cho-
langiocarcinomas (13%) and peri-hilar adenocarcinomas
(33%). KRAS mutations were not identified in gallblad-
der carcinomas and extra-hepatic cholangiocarcinomas.
In general, reported rates of KRAS mutation are some-
what lower in these sites than intra-hepatic cancers (3-
20%) [3,16,32] with a notable exception being neoplasms
that arise in the setting of an anomalous union of the
pancreatic and biliary ducts, which have higher rates of
KRAS mutation [5]. None of the cases in this series had
evidence of an anomalous anatomy of the bile ducts.
While our results from the gallbladder are similar to
that reported in literature, the data on extra-hepatic
neoplasm differs from prior reports that suggest 10-15%
of extra-pancreatic cholangiocarcinomas harbor muta-
tions in the KRAS gene [3,15]. In this series, KRAS
mutations were not identified in any of the adenocarci-
nomas arising from the mid-portion of the bile duct or
t h ei n t r a - p a n c r e a t i cp o r t i o no ft h eb i l ed u c t .I ti sp o s s i -
ble that the KRAS mutations identified in extra-hepatic
bile duct carcinomas in prior studies may represent
cases of peri-biliary pancreatic ductal adenocarcinoma.
Histology remains the gold standard for distinguishing
distal bile duct carcinomas from pancreatic ductal ade-
nocarcinomas, and this distinction is based primarily on
the pattern of infiltration and the relationship of the
tumor to the bile duct. Nonetheless, there is significant
overlap in the histologic appearance of these two neo-
plasms. We did not detect any KRAS mutation among
the 13 distal extra-hepatic and intrapancreatic biliary
carcinoma. Analysis of the absence of KRAS mutations
in extra-hepatic and intrapancreatic biliary carcinoma in
comparison to the 4 mutations identified intrahepatic
and perihilar cholangiocarcinomas shows this relation-
ship to be insignificant, p = 0.28 (Fishers exact test). It
is possible that the absence of KRAS mutations in extra-
hepatic cancers in our screen was a chance event. It is
Table 4 Mutational Spectrum of Oncogenes and Tumor
Suppressor Genes
Gene GBC (%) EHCC (%) IHCC (%) Method Refs.
CTNNB1/
b-CATENIN
5 SEQ [33]
9 0 SEQ [34]
0 SEQ [35]
KRAS 38 PCR-SSCP [5]
20 PCR-RFLP [16]
19 PCR-RFLP [32]
3 15 SEQ [3]
10 PCR-SSCP [15]
54 SEQ [6]
45 SEQ [2]
48 SEQ [36]
0 0 13 OncoMap
BRAF 33 SEQ [7]
22 SEQ [2]
0 0 0 SEQ & GLCR [8]
EGFR 9 18 20 SEQ [9]
6 SEQ [10]
12 5 10 IHC and FISH [37]
PIK3CA 4 0 9 SEQ [11]
13 0 0 OncoMap
ERBB2/
HER-2
16 5 0 IHC and FISH [37]
P16INK4A 31 SSCP [16]
62 55 numerous [13]
88 numerous [6]
TP53 36 SSCP [16]
33 PCR-SSCP [15]
37 SEQ [14]
SMAD4 16 PCR-SSCP [12]
55 13 IHC [38]
STK11/LKB1 6 SEQ [39]
Abbreviations: GBC; gallbladder carcinoma, IHCC; intra-hepatic
cholangiocarcinoma, EHCC; extra-hepatic cholangiocarcinoma, SEQ;
sequencing, PCR-SSCP; polymerase chain reaction single-strand confirmation
polymorphism, RFLP; restriction fragment length polymorphism, GLCR; gap
ligase chain reaction.
Deshpande et al. BMC Cancer 2011, 11:60
http://www.biomedcentral.com/1471-2407/11/60
Page 5 of 7also, however, possible that intra-hepatic and perihilar
cholangiocaricinomas may differ genetically from more
distal bile duct carcinomas.
While this study identified known mutations and
points towards an association between PIK3CA muta-
tions and GBC, the rates of validated mutations in genes
such as KRAS, particularly in the intra-hepatic cholan-
giocarcinomas, were lower than expected given the find-
ings of previous studies [2-6]. Additionally, other
previously identified mutations in genes such as BRAF
and EGFR were not identified here [2,10]. Potential rea-
sons for this could include a diminished sensitivity of
t h ea s s a ya m o n go u rs a m p l es e t .T h i sc o u l db ed u et o
dilution of tumor-derived nucleotides by tumor asso-
ciated desmoplasia and stroma- a common feature of
BTC. By selecting tumor specimens with ~50% or
higher cellularity we had attempted to diminish the
impact of this. Alternatively, these mutations may be
present at only a low incidence or not at all. Among the
three previously published studies BRAF mutations are
identified in ~20% of cases in two European BTC collec-
tions including both GBC and intra-hepatic CC [2,7].
No BRAF mutations were found in an American cohort
[8]. This is echoed in the above findings. In spite of the
extensive mutational analysis (Additional file 1 Table S1
and Additional file 1 Table S3), we did not identify any
additional new mutations in biliary tract carcinomas.
Conclusions
The molecular characterization of subgroups of tumors
has become critical to development of new classes of
anti-cancer agents. Inhibitors of the PI3K pathways are
presently in development including specific inhibitors of
p110alpha that have demonstrated efficacy in engineered
preclinical models of lung cancer harboring activating
point mutations in PIK3CA [27]. These results, pointing
towards an enrichment of activating PIK3CA mutations
in GBC, suggest a potential group of patients with GBC
who may also benefit from these agents. Further muta-
tional profiling efforts across larger cohorts of BTC are
needed to confirm these results and better define geneti-
cally distinct subsets of cancers.
Additional material
Additional file 1: Supplementary Table 1-3. Table S1: All mutations
included in initial OncoMap screen. Table S2: Listing of mutations
identified in initial OncoMap screening. 115 candidate mutations across
24 genes in 65% (47/72) of samples were identified. These were then
ranked into two groups based on the mass spectrometric profiles and
the likelihood that these represent true mutations referred to as
conservative and aggressive “calls” which comprised 10% (12/115) and
90% (103/115) of possible mutations, respectively. Table S3: Candidate
mutations across 12 genes (ABL1, APC, BRAF, EGFR, FGFR3, FLT3, KIT,
KRAS, NRAS, PDGFRA, PIK3CA, MYC,) screened in hME validation assay on
non WGA DNA using independent primers and probes.
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